DICRONIS: CONVERT RESEARCH INTO A PRODUCT
Dicronis is a start-up company that develops innovative pharmaceutical products for the early diagnosis of diseases with high and urgent medical needs. The first product, Lymphit, controls the function of the lymphatic system in a simple, safe and economical way, even from home. Thus contributing to drastically reduce, in combination with a specific treatment, the development of lymphoedema, a serious side effect of certain cancer therapies, to which up to one million patients are at risk annually, in Europe alone.
Dicronis was the winning project of the MedTech Business 2017 Award, conferred during the MedTech Business Comprehensive Advanced Program on MedTech Entrepreneurship at USI (which took place from November 27 to December 1, 2017).
The start-up was also the winner of StartCup Ticino 2017, the competition that awards the most innovative and promising business ideas realized in Ticino – an initiative of the USI-SUPSI Start-Up Promotion Center (CP Start-Up).
Thanks to her project, Patrizia Marschalkova, CEO of Dicronis, won the full EMBA scholarship.
Dicronis was a project developed during her Master’s degree studies at ETH Zurich. This eventually led to the idea of converting research into a product for the early diagnosis of lymphedema, a complication of cancer therapies. In this way, patients can begin with therapies before the condition becomes irreversible.
She recently attended the MedTech Business program at USI, after which she also competed (and won) the StartCup Ticino 2017 competition.
The StartCup Ticino competition, thanks also to the so-called “accelerator” phase, gave her the opportunity to focus on the business aspects of a start-up company like Dicronis, for instance by creating a good business plan for investors. The combination of these two programs and the learnings acquired helped the colleagues and her at Dicronis to finalize a solid financial and development plan for her company.